Weisner, Jörn <br/><br/>
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in   [electronic resource] 

 -  Cancer research  05 2019 
 - 2367-2378 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-18-2861  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis<br/>Cell Cycle<br/>Cell Proliferation<br/>Colorectal Neoplasms--drug therapy<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Mice<br/>Mice, Nude<br/>Mutation<br/>Pancreatic Neoplasms--drug therapy<br/>Proto-Oncogene Proteins c-akt--antagonists & inhibitors<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Pyridones--pharmacology<br/>Pyrimidinones--pharmacology<br/>Tumor Cells, Cultured<br/>Xenograft Model Antitumor Assays